Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Announces Clinical Protocol Approval of CEQ508 at Massachusetts General Hospital

BOTHELL, WA--(Marketwire - November 03, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced institutional site approval at Massachusetts General Hospital (MGH), for their clinical trial protocol for Familial Adenomatous Polyposis (FAP), allowing trial initiation including patient enrollment and dosing. The protocol was independently reviewed and approved by the Institutional Review Board (IRB) and the Institutional Biosafety Committee (IBC) at MGH, a world class medical center and clinical trial site. The trial, consisting of two phases, is designed to determine safety and tolerability of CEQ508, which is both the company's first RNAi-based therapeutic to reach human clinical trials and the first orally administered RNAi-based therapeutic to reach human clinical trials. In addition, the company announced the trial's Principal Investigator and the formation of a Data Safety Monitoring Board (DSMB) responsible for overall safety decisions in addition to reviewing data between phases.

"Clinical site approval at MGH marks the last regulatory requirement prior to moving our first drug candidate into human trials," said J. Michael French, President and CEO of Marina Biotech. "CEQ508 utilizes our orally administered, transkingdom RNAi technology which provides an extremely efficient and convenient approach to delivery of an RNAi-based therapeutic. We are also pleased to announce a world-class team of clinical investigators who will form our DSMB. With the pending dosing of CEQ508 in patients with FAP, we become one of the few RNAi companies with programs in clinical development."

The CEQ508 trial will be conducted under the guidance of Daniel C. Chung, M.D., Clinical Chief, Gastrointestinal Unit and Director, High Risk GI Cancer Clinic at MGH who will serve as the trial's Principal Investigator. Marina Biotech's Data Safety Monitoring Board (DSMB) is comprised of accomplished scientific and medical leaders of the gastrointestinal community and will function as the safety review committee throughout both phases of the trial. Committee members include Anil K. Rustgi, M.D., T. Grier Miller Professor of Medicine and Chief, Division of Gastroenterology at the University of Pennsylvania; Fay Kastrinos, M.D., M.P.H., Assistant Professor of Medicine and Director, Familial Colon Cancer Clinic at Columbia University Medical Center; and Kenneth Hung, M.D., Ph.D., Assistant Professor of Medicine at Tufts Medical Center.

CEQ508 is the first drug candidate in a novel class of therapeutic agents utilizing the transkingdom RNA interference (tkRNAi) platform. CEQ508 comprises attenuated bacteria that are engineered to enter into dysplastic tissue and release a payload of short-hairpin RNA (shRNA), a mediator in the RNAi pathway. The shRNA targets the mRNA of beta-catenin, which is known to be dysregulated in classical FAP. CEQ508 is being developed as an orally administered treatment to reduce the levels of beta-catenin protein in the epithelial cells of the small and large intestine. Upon enrollment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. CEQ508 will be administered daily in an oral suspension for 28 consecutive days. For more information please contact clinicaltrials@marinabio.com.

About FAP

CEQ508 is being developed for the treatment of Familial Adenomatous Polyposis (FAP), a hereditary condition that occurs in approximately 1:10,000 persons worldwide. FAP is caused by mutations in the Adenomatous Polyposis Coli (APC) gene. As a result of these mutations, epithelial cells lining the intestinal tract have increased levels of the protein beta-catenin, which in turn, results in uncontrolled cell growth. Proliferation of the epithelial cells results in the formation of numerous (hundreds to thousands) non-cancerous growths (polyps) throughout the large intestine. By age 35, 95% of individuals with FAP have developed polyps and most will experience adverse effects including increased risk of bleeding and the potential for anemia. In more severe cases, obstruction of the intestines, abdominal pain, and severe bouts of diarrhea or constipation can occur. FAP patients are also at an increased risk of various cancers, the most concerning of which is a nearly 100% occurrence of colon cancer if measures are not taken to prevent the formation of polyps. For many patients, complete colectomy (surgical removal of the entire large intestine), usually performed in the late teenage years or early twenties, is the only viable option for treatment. However, surgical intervention is not curative as the risk of polyps forming in the remaining portions of the intestinal tract and in the small intestine continues after colectomy.

About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.